TABLE 3.
Associations between the GRIK2, TRPV1, TRPV3 and TRPM8 gene polymorphisms and the risk of migraine.
| SNPs/genotypes/genetic models | Control No. (%) | Migraine No. (%) | OR (95% CI) | p | ORadj (95% CI) | p |
|---|---|---|---|---|---|---|
| GRIK2-rs2227283 G>A | ||||||
| GG | 269 (44.83) | 103 (41.04) | ref | ref | ||
| GA | 249 (41.50) | 124 (49.40) | 1.30 (0.95–1.78) | 0.100 | 1.28 (0.91–1.80) | 0.162 |
| AA | 82 (13.67) | 24 (9.56) | 0.76 (0.45–1.26) | 0.300 | 0.74 (0.42–1.26) | 0.277 |
| Dominant model | 1.50 (0.94–2.47) | 0.100 | 1.54 (0.93–2.65) | 0.105 | ||
| Recessive model | 1.38 (1.02–1.85) | 0.034 | 1.36 (0.99–1.89) | 0.062 | ||
| Additive model | 0.73 (0.54–0.98) | 0.034 | 0.73 (0.53–1.02) | 0.062 | ||
| TRPV1-rs8065080 C>T | ||||||
| CC | 212 (35.33) | 95 (37.85) | ref | ref | ||
| TC | 287 (47.83) | 128 (51.00) | 1.00 (0.72–1.37) | 0.977 | 0.92 (0.65–1.31) | 0.650 |
| TT | 101 (16.83) | 28 (11.16) | 0.62 (0.38–0.99) | 0.052 | 0.55 (0.32–0.92) | 0.025 |
| Dominant model | 1.61 (1.04–2.56) | 0.036 | 1.75 (1.09–2.90) | 0.025 | ||
| Recessive model | 1.14 (0.85–1.53) | 0.400 | 1.09 (0.79–1.50) | 0.603 | ||
| Additive model | 0.88 (0.66–1.18) | 0.400 | 0.92 (0.67–1.27) | 0.603 | ||
| TRPV3-rs7217270 G>A | ||||||
| GG | 535 (89.17) | 210 (83.67) | ref | ref | ||
| AG | 62 (10.33) | 38 (15.14) | 1.56 (1.01–2.40) | 0.044 | 1.59 (0.98–2.55) | 0.056 |
| AA | 3 (0.50) | 3 (1.20) | 2.55 (0.47–13.86) | 0.254 | 2.28 (0.39–13.39) | 0.340 |
| Dominant model | 1.61 (1.05–2.44) | 0.028 | 1.63 (1.02–2.58) | 0.039 | ||
| Recessive model | 2.40 (0.32–18.07) | 0.368 | 1.58 (0.98–2.53) | 0.060 | ||
| Additive model | 0.65 (0.99–0.42) | 0.047 | 0.63 (0.40–1.03) | 0.060 | ||
| TRPM8-rs7577262 G>A | ||||||
| GG | 220 (36.67) | 116 (46.22) | ref | ref | ||
| GA | 294 (49.00) | 105 (41.83) | 0.68 (0.49–0.93) | 0.016 | 0.76 (0.54–1.07) | 0.120 |
| AA | 86 (14.33) | 30 (11.95) | 0.66 (0.41–1.05) | 0.087 | 0.70 (0.41–1.15) | 0.166 |
| Dominant model | 1.23 (0.80–1.95) | 0.357 | 1.25 (0.78–2.06) | 0.366 | ||
| Recessive model | 0.75 (0.56–1.01) | 0.056 | 0.83 (0.60–1.15) | 0.258 | ||
| Additive model | 1.34 (0.99–1.80) | 0.056 | 1.21 (0.87–1.67) | 0.258 | ||
| TRPM8-rs17862920 C>T | ||||||
| CC | 321 (53.50) | 157 (62.55) | ref | ref | ||
| CT | 237 (39.50) | 82 (32.67) | 0.71 (0.52–0.97) | 0.031 | 0.77 (0.54–1.09) | 0.141 |
| TT | 42 (7.00) | 12 (4.78) | 0.58 (0.29–1.11) | 0.115 | 0.66 (0.30–1.33) | 0.258 |
| Dominant model | 1.50 (0.80–3.02) | 0.229 | 1.38 (0.69–2.95) | 0.383 | ||
| Recessive model | 0.74 (0.54–1.01) | 0.061 | 0.80 (0.57–1.12) | 0.203 | ||
| Additive model | 1.35 (0.99–1.84) | 0.061 | 1.25 (0.89–1.76) | 0.203 |
Bold type indicates p < 0.05. ORadj (95% CI) adjusted factors: age, sex, BMI, marital status, nationality, educational level, smoking, alcohol, exercise, history of hypertension, history of diabetes, family history of diabetes, family history of migraine, SAS grade, PHQ9 grade, PSQI grade.
GRIK2, glutamate ionotropic receptor kainate type subunit 2; TRPV1, transient receptor potential cation channel subfamily V member 1; TRPV3, transient receptor potential cation channel subfamily V member 3; TRPM8, transient receptor potential cation channel subfamily M member 8.